Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Sets Strategy For Global Infant Formula Growth

This article was originally published in The Tan Sheet

Executive Summary

The private labeler’s more than 60 planned product launches include Codex-compliant infant formulas. The firm also sees marketing formula in plastic containers as a U.S. sales driver.

You may also be interested in...



Bloom & Blossom Sprouts Perrigo Into Branded Formula Space

The firm launches Bloom & Blossom Ultra Gentle Formula soon after beginning to report international sales growth driven by branded OTC drugs and nutritional supplements. The latest brand move comes less than a week before Mylan tenders its hostile takeover offer to Perrigo shareholders.

Bloom & Blossom Sprouts Perrigo Into Branded Formula Space

The firm launches Bloom & Blossom Ultra Gentle Formula soon after beginning to report international sales growth driven by branded OTC drugs and nutritional supplements. The latest brand move comes less than a week before Mylan tenders its hostile takeover offer to Perrigo shareholders.

Perrigo’s Irish Move Sets Stage For International Boost, Net Revenue Gain

OTC private label leader Perrigo acquires Irish firm Elan for $8.6 billion in a deal that will bring tax savings from being incorporated in Ireland, provide a stage for European expansion and tap into Elan’s royalty rights. “Simply stated, we're going to be able to further our international platform,” CEO Joseph Papa says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel